Short answer
CYTOKINETICS INC (CYTK) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
CYTOKINETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 with detailed financial results
- Investor focus: earnings performance and updates disclosed in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q2 MYQORZO revenue reached $25.3M, including $23.0M U.S. sales and $2.3M from European distributor inventory
- Commercial traction: over 700 prescribers, approximately 1,500 patients dispensed, and over 80% on paid prescriptions
- ACACIA-HCM met both primary endpoints, supporting a supplemental NDA submission for non-obstructive HCM in Q4 2026
- Cash, equivalents and investments rose to approximately $1.7B after an $760.1M net equity offering, strengthening launch and pipeline funding
- Net loss widened to $198.8M, while 2026 combined R&D and SG&A guidance increased to $860M-$890M for commercial readiness investments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CYTOKINETICS INC 8-K filings
Get the next CYTK 8-K as it lands
Follow CYTK for push alerts, or ask the research agent what this filing means.